Table 3: Life table distribution of probability of immunological failure of patients on HAART  St.Luke and Tulu Bolo Hospital, Ethiopia, April 2006-July 2013

 

*Interval Start Time

Number Entering Interval

Number Withdrawing during Interval

Number Exposed to Risk

Number of Terminal Events

Proportion Terminating

Proportion Surviving

Cumulative Proportion Surviving at End of Interval

0

65

0

65.000

0

0.00

1.00

1.00

6

65

0

65.000

0

0.00

1.00

1.00

12

65

0

65.000

0

0.00

1.00

1.00

18

65

0

65.000

0

0.00

1.00

1.00

24

65

1

64.500

10

0.16

0.84

0.84

30

54

0

54.000

7

0.13

0.87

0.74

36

47

1

46.500

3

0.06

0.94

0.69

42

43

2

42.000

11

0.26

0.74

0.51

48

30

1

29.500

4

0.14

0.86

0.44

54

25

0

25.000

3

0.12

0.88

0.39

60

22

1

21.500

8

0.37

0.63

0.24

66

13

2

12.000

1

0.08

0.92

0.22

72

10

0

10.000

5

0.50

0.50

0.11

78

5

0

5.000

3

0.60

0.40

0.04

84

2

1

1.500

1

0.67

0.33

0.01

Six month interval was taken from the WHO and National guide line which is recommended for immunological follow-up